skip to Main Content

Cheap Stroke Drug Boosts Pancreatic Cancer Survival in Mice

Newsfeed image, light gray text on dark gray background
A drug that is already used to treat strokes can significantly prolong the survival of mice with pancreatic cancer.

Pancreatic cancer has the worst survival rate of any major cancer. The standard chemotherapy combination of gemcitabine and nab-paclitaxel (Abraxane) only keeps patients alive for an average of nine months. Treatment is difficult because pancreatic tumours are protected by an armour of connective tissue, blood vessels and immune cells, known collectively as the stroma. Read more . . .

Back To Top